1 / 25

Thrombolysis for patients > 80 – a different view

Thrombolysis for patients > 80 – a different view. Peter Sandercock On behalf of the IST3 collaborative Group . UKSF Glasgow 1 st December 2009. Some questions. Why does age > 80 matter? Are people >80 years getting rt-PA? For people aged > 80 vs < 80 yrs Are the benefits different?

hagen
Download Presentation

Thrombolysis for patients > 80 – a different view

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Thrombolysis for patients > 80 – a different view Peter Sandercock On behalf of the IST3 collaborative Group UKSF Glasgow 1st December 2009

  2. Some questions • Why does age > 80 matter? • Are people >80 years getting rt-PA? • For people aged > 80 vs < 80 yrs • Are the benefits different? • Are the risks(intracranial haemorrhage) different? 4. Is there a role for specialist brain imaging to sort out which older patients should receive thrombolysis? 5. Do we need more trials in the over 80s?

  3. Why does it matter? • It’s a big problem • Every year in the UK ~ 30,000 people aged > 80 have an acute ischaemic stroke • EU approval for thrombolysis excludes > 80 year olds • Ageism in rt-PA usage

  4. Ageism: the older you are, the less likely you are to get rt-PA for stroke: Germany Age Förch. Stroke 2009;40:1900-2

  5. Randomised trial evidence for rt-PA in the over 80’s? 11 randomised trials of rt-PA for stroke 3977 patients Only 42 patients aged > 80 years! Wardlaw J et al, Cochrane Database Systematic Reviews 2009

  6. In patients aged < 80: effect on death Non-significant 14% increase in odds of death (95% CI, 5% reduction to 38% increase) OR 1.14 (0.95-1.38) Wardlaw J, Cochrane Database Systematic Reviews 2009

  7. Non-randomised cohort studies. Outcome after iv thrombolysis for stroke > 80 versus <80 years of age: • 6 cohort studies included • 2,244 patients • 477 aged ≥80 years • Potential for bias - can’t adjust for baseline differences in those < and > 80 years Engelter. Age and Ageing 2006; 35: 572–580

  8. Non-randomised cohorts: Death People aged > 80 more likely to die with rt-PA Engelter. Age and Ageing 2006; 35: 572–580

  9. Non- randomised cohorts: good outcome in survivors (mRS 0-1) People aged > 80 less likely to survive with a good outcome after rt-PA Engelter. Age and Ageing 2006; 35: 572–580

  10. Summary of non-random studies • Imbalances in baseline variables; hard to assess balance of risk and benefit • Need reliable randomised evidence on the balance of risk and benefit • For stroke patients aged ≥80 years, it is safe and reasonable to include such patients in randomised placebo-controlled trials. Engelter. Age and Ageing 2006; 35: 572–580

  11. Third International Stroke Trial. A large randomised trial to answer the question: can a wider variety of patients be treated with iv therapy? Target: 3100 patients from ~ 100 centres in 12 Countries by mid 2011

  12. IST-3 trial: randomisation If patient fits main eligibility/exclusion criteria, Clinician/patient/family discuss. If: • Clear INDICATION FOR rt-PA TREAT (i.e. meets terms of current licence and patient agrees) • Clear CONTRAINDICATION TO rt-PA  DON’T TREAT • rt-PA ‘PROMISING BUT UNPROVEN’ RANDOMISE

  13. Randomised trials with IST-3 design (to include > 80’s) applauded • … will inevitably include patients with comorbidities, but we need to embrace frailty… • … must be flexible and use creative strategies to facilitate participation of older individuals in clinical trials. • … endpoints that are relevant to older individuals should be assessed: … physical handicap, … quality of life.’ Lancet Neurology. Editorial 2009

  14. Number of patients recruited per quarter year in each age and time stratum ECASS-3 published Age time(h)

  15. Imaging for selection??? • Structural • CT WM lesions, atrophy, old strokes • MR Microbleeds, white matter lesions, atrophy • Angiography • CT • MR • Perfusion • CT • MR No reliable RCT evidence!

  16. Ongoing randomised trials IST-3 all ages < 6hrs. target = 3100 patients • Predicted 1000 patients > 80 years • To date IST-3 has recruited more than 800 patients > 80 years: • 300/800 (37%) recruited 0 - 3 hrs • 640/800 (79%) recruited 0 - 4.5 hrs • More UK centres welcome TESPI 600 patients > 80 years < 3hrs • To date recruited 36 patients

  17. Summary: rt-PA for the over 80’s Why does it matter? In the UK30,000 people/yraged > 80 have an acute stroke! Are they getting rt-PA? Very few, and variably! For people aged > 80 vs < 80 yrs: Are the benefits different? Don’t know! Are the risks different? Don’t know! Specialist brain imaging to select? Don’t know! Need more RCT evidence in over 80s? YES

  18. Main features of IST - 3 • International, multi-centre, Prospective, Randomised, Open, Blinded Endpoints (PROBE) design study of i.v. rt-PA vs control. Independent. Investigator-led • Primary outcome: the proportion of patients alive and independent at six months (Modified Rankin 0,1 or 2) • Randomisation by telephone or internet with on-line minimisation to balance key prognostic factors. • Blinded central review of all scans • Recruitment ends mid 2011, results early 2012

  19. USA: Increasing age reduces odds of treatment with rt-PA: Reduction (compared with age < 60) p Age 60-69* 30% 0.07 Age 70-79* 30% 0.003 Age 80-89* 60% < 0.001 Age 90 + * 80% < 0.001 * Survey of 23,058 ischemic strokes in 137 US hospitals. Reed et al, Stroke 2001; 32: 1832-1840

  20. Neurology in the elderly: more trials urgently needed1 • the average age of participants in the NINDS trial of alteplase for acute stroke was 67 years1 • patients aged 80 years and older were specifically excluded from the post-registration studies;1 • consequently, alteplase is not licensed for use in patients older than 80 years.1 • ‘…the International Stroke Trial (IST-3), which is including substantial numbers of patients in this age-group, will definitively assess the effectiveness of alteplase for the very elderly’2 1. Editorial Lancet Neurology 2009. 2.Sanossian. Lancet Neurology 2009

  21. Patient selection from thrombolysis – does CTA, CTP, MRA or MRP add anything (or just delay the start of treatment)? • DIAS 1& 2 RCTs – ‘we know the answer already’ - MR DWI PWI ‘mismatch’ must be present: trials negative • EPITHET – RCT, but too small to say whether presence or absence of mismatch is helpful • DEFUSE – no control group!!!! • DIAS-3&4 – ‘we know the answer already’ - need to show a blocked artery to benefit • EXTEND – no, you need ‘penumbral mismatch’ to select • IST-3 aiming to collect pre-randomisation data on perfusion, angiography or both in 100-300 patients

  22. Stroke thrombolysis > 80 years • Patients over 80 have been excluded from randomised trials and hence from the licence • 2 randomised trials are recruiting patients > 80 • IST-3 will recruit > 1000 patients > 80yr (800 already) • Italian trial (TESPI) recruiting patients > 80yr < 3hrs. (36 to date)

  23. Effect of IV rt-PA < on ‘death or dependency’: age < 80 926 999 Heterogeneity (Chi2 p=0.007) I2 = 62% Test for overall effect p=0.0001 Wardlaw J et al, Cochrane Database Systematic Reviews 2009

  24. Symptomatic ICH Engelter. Age and Ageing 2006; 35: 572–580

More Related